Journal article
Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions
Clinical transplantation, v 25(5), pp E475-E486
01 Sep 2011
PMID: 21592231
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Although malignancy is a major threat to long-term survival of heart transplant (HT) recipients, clear strategies to manage immunosuppression in these patients are lacking. Several lines of evidences support the hypothesis of an anticancer effect of proliferation signal inhibitors (PSIs: mammalian target of rapamycin [mTOR] inhibitors) in HT recipients. This property may arise from PSI's ability to replace immunosuppressive therapies that promote cancer progression, such as calcineurin inhibitors or azathioprine, and/or through their direct biological actions in preventing tumor development and progression. Given the lack of randomized studies specifically exploring these issues in the transplant setting, a collaborative group reviewed current literature and personal clinical experience to reach a consensus aimed to provide practical guidance for the clinical conduct in HT recipients with malignancy, or at high risk of malignancy, with a special focus on advice relevant to potential role of PSIs.
Metrics
Details
- Title
- Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions
- Creators
- E. Epailly - Hôpitaux Universitaires de StrasbourgJ. Albanell - Medical Oncology Department, Hospital del Mar, IMIM, Autonomous University of Barcelona, Barcelona, SpainA. Andreassen - Oslo University HospitalC. Bara - Medizinische Hochschule HannoverJ. M. Campistol - Hospital Clínic de BarcelonaJ. F. Delgado - Hospital Universitario 12 De OctubreH. Eisen - Hahnemann University HospitalA. E. Fiane - University of OsloP. Mohacsi - University of BernS. Schubert - Deutsches Herzzentrum der CharitéL. Sebbag - Hôpital Louis PradelF. M. Turazza - Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano NiguardaH. Valantine - Stanford UniversityA. Zuckermann - Medical University of ViennaL. Potena - University of Bologna
- Publication Details
- Clinical transplantation, v 25(5), pp E475-E486
- Publisher
- Wiley
- Number of pages
- 12
- Grant note
- Novartis Pfizer Novartis Pharma (Basel, CH) Novartis Germany; Novartis Genzyme; Sanofi-Aventis; Genzyme Corporation Cls Behring
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000296262300002
- Scopus ID
- 2-s2.0-80054122390
- Other Identifier
- 991019335320604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Surgery
- Transplantation